Navigation Links
Speedus Announces Fourth Quarter and Fiscal 2007 Results
Date:3/31/2008

NEW YORK, March 31 /PRNewswire-FirstCall/ -- Speedus Corp. (Nasdaq: SPDE) today announced a net loss of $4.4 million, or $1.11 per share on a fully diluted basis, for the twelve months ended December 31, 2007 compared to a net loss of $5.6 million, or $1.40 per share on a fully diluted basis, for the twelve months ended December 31, 2006. The loss before depreciation and amortization for the twelve months ended December 31, 2007 was $4.2 million compared to a loss before depreciation and amortization of $4.9 million for the twelve months ended December 31, 2006.

For 2007, total operating expenses before depreciation and amortization amounted to $5.7 million compared to $6.3 million in 2006. This decrease is primarily a result of a decrease in non-cash stock based compensation.

In October 2007, Zargis and the 3M Company entered into an exclusive multi-year marketing alliance involving Zargis' heart sound analysis software and 3M Littmann's next-generation electronic stethoscope. Under the agreement, Zargis will support 3M in its efforts to develop a next-generation stethoscope that will be compatible with Zargis' heart sound analysis software. In addition, the alliance provides Zargis with a wide-range of marketing and promotional opportunities along with exclusive rights to sell its heart sound analysis software through the global distribution network of the Littmann brand. The agreement grants 3M a 10% minority equity position in Zargis, 5% following the first sale of Zargis' software through the 3M distribution channel and 5% in the event the agreement is renewed after an initial two year term and certain other conditions are met, and a seat on Zargis' board of directors.

About Speedus Corp

Additional information on Speedus Corp. may be obtained at http://www.speedus.com or by contacting Peter Hodge at 888-773-3669 (ext. 23) or phodge@speedus.com.

Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.

These financial statements do not include all information and notes required by generally accepted accounting principles for complete financial statements. These financial statements should be read in conjunction with the Company's 2007 audited consolidated financial statements and notes thereto on Form 10-K. Operating results for the year ended December 31, 2007 are not necessarily indicative of the results that may be expected for the year ending December 31, 2008.

CONTACT: Peter Hodge of Speedus Corp., 888-773-3669 (ext. 23) or phodge@speedus.com

SPEEDUS CORP.

CONSOLIDATED STATEMENTS OF OPERATIONS

Quarters ended Years ended

December 31, December 31,

2007 2006 2007 2006

(unaudited) (unaudited)

Revenues $155,285 $208,024 $733,213 $846,342

Expenses:

Selling, general and

administrative 1,022,009 1,157,638 3,828,009 4,319,554

Research and

development 354,315 293,793 1,612,872 1,678,139

Depreciation and

amortization 109,201 139,888 265,634 757,553

Cost of sales 65,825 76,717 297,439 306,932

Total operating

expenses 1,551,350 1,668,036 6,003,954 7,062,178

Operating loss (1,396,065) (1,460,012) (5,270,741) (6,215,836)

Investment

income/(loss) (10,148) 332,532 852,691 600,641

Net loss $(1,406,213) $(1,127,480) $(4,418,050) $(5,615,195)

Per share:

Loss per common share

- basic and diluted $(0.35) $(0.28) $(1.11) $(1.40)

Weighted average

common shares

outstanding - basic

and diluted 3,991,910 4,004,279 3,992,044 4,012,927

SPEEDUS CORP.

CONSOLIDATED BALANCE SHEETS

December 31,

2007 2006

ASSETS

Current assets:

Cash and cash equivalents $8,845,358 $10,204,167

United States Treasury bills 2,996,700 4,990,250

Assets held for sale 342,000 ---

Marketable securities 92,190 354,011

Prepaid expenses and other 79,623 143,654

Total current assets 12,355,871 15,692,082

Property and equipment, net of

accumulated depreciation of

$112,353 and $444,972 50,569 527,828

Other intangible assets, net of

accumulated amortization of

$1,125,928 in 2006 --- 34,116

Other investments 800,000 800,000

Other assets 83,127 81,737

Total assets $13,289,567 $17,135,763

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $46,413 $62,805

Accrued liabilities 1,390,803 971,055

Total current liabilities 1,437,216 1,033,860

Commitments and Contingencies

Stockholders' equity:

Common stock ($.01 par value;

50,000,000 shares authorized;

5,438,006 shares issued) 54,380 54,380

Preferred stock ($.01 par

value; 20,000,000 shares

authorized):

Series A Junior

Participating ($.01 par

value; 4,000 shares

authorized; no shares

issued and outstanding) --- ---

Additional paid-in-capital 91,797,457 91,627,241

Treasury stock (at cost;

1,445,634 and 1,445,221 shares) (6,085,078) (6,083,360)

Accumulated deficit (73,914,408) (69,496,358)

Stockholders' equity 11,852,351 16,101,903

Total liabilities and

stockholders' equity $13,289,567 $17,135,763


'/>"/>
SOURCE Speedus Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hillenbrand Industries, Inc. Announces Expiration and Final Results of its Previously Announced Any and All Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009
2. Bally Total Fitness Announces Interim Chapter 11 Plan Distribution to Former Stockholders
3. MINRAD International, Inc. Announces 2007 Financial Results
4. CalbaTech Announces $999,926 Reduction in Debt; First Adult Stem Cell Harvesting Scheduled
5. ReBuilder Medical Technologies, Inc. Announces Best Sales Day in 5 Years
6. Milestone Scientific Announces 2007 Year-End Results
7. LCA-Vision Announces the Opening of its 76th LasikPlus(R) Vision Center in Woodbridge, New Jersey
8. China Yingxia International, Inc. Announces Record Fourth Quarter and Year 2007 Results
9. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
10. LifeCare Holdings, Inc. Announces Year-end Results
11. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... 2016 , ... An April Gallup survey found rising health care costs to ... Sun Health Senior Living (SHSL) may not share those same worries thanks to ... for the year, while holding the line on increasing their contributions, including premiums, deductibles ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of Life Science ... the organization has earned its ISO 13485 certification, indicating the company’s quality control ... rules and policies associated with ISO quality standard 13485. , BSI Group ...
(Date:5/26/2016)... Texas (PRWEB) , ... May 26, 2016 , ... ... Friday, May 13 at Blackhorse Golf Club in Cypress. With the help of community ... non-profit that restores, empowers, and renews hope for wounded service members and their families ...
(Date:5/26/2016)... ... May 26, 2016 , ... The MIAMI Institute for Age Management and ... Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness Physician of the MIAMI Institute ... of the Institute for Functional Medicine. , He also heads up FITTLab, the comprehensive ...
(Date:5/26/2016)... ... ... Bunion Bootie , the manufacturer of the newest and best in ... customer demand over the Mother’s Day Weekend promotion. So much so, that they completely ... completely replenished its inventory levels, it hopes to continue its current sales pace, and ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... ReportsnReports.com adds "Chronic Cough ... provides an overview on therapeutic pipeline of Chronic ... therapeutics assessment by drug target, mechanism of action ... along with latest updates, and featured news and ... in the therapeutic development for Chronic Cough and ...
(Date:5/24/2016)... 2016  Diana Russell suffers from a form of ... inside out.  This disease has put her in a ... and grandchildren to leave her home.  Because of the ... haul the wheelchair.  So if there is a family ... is left to wait for the bus. ...
(Date:5/24/2016)... May 24, 2016 The ... world , s first dual therapy stent, ...   OrbusNeich, a global company specializing in ... portfolio to include products to treat peripheral artery disease. ... first entry devices for lower limb and arteriovenous (AV) ...
Breaking Medicine Technology: